Could a cancer therapy tame severe lupus? early trial launches

NCT ID NCT05798117

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new treatment called YTB323, a type of CAR T-cell therapy, in 21 adults with severe lupus that hasn't improved with standard treatments. The goal is to see if a single infusion is safe and can control the disease. Researchers will also measure how long the modified cells last in the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: YTB323 (a CAR T-cell therapy)
What this could lead to: If it works, this could point toward a new treatment option for people with severe lupus that hasn't responded to other therapies.
What could go wrong: This is a very early, small study (21 people) focused on safety. CAR T-cell therapy can cause serious side effects, and it's unknown if it will work for lupus long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lupus nephritis systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUPUS NEPHRITIS SYSTEMIC LUPUS ERYTHEMATOSUS

Contacts and locations

Locations

Novartis Investigative Site

Clayton, Victoria, 3168, Australia
Novartis Investigative Site

Paris, 75013, France
Novartis Investigative Site

Pessac, 33604, France
Novartis Investigative Site

Strasbourg, 67091, France
Novartis Investigative Site

Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany
Novartis Investigative Site

Mainz, 55131, Germany
Novartis Investigative Site

Barcelona, 08035, Spain
Novartis Investigative Site

Madrid, 28009, Spain
Novartis Investigative Site

Bern, 3010, Switzerland
Novartis Investigative Site

Lausanne, 1011, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.